PRTA's net losses substantially increased while the company burned through nearly $164 million in cash during the year, reducing its financial runway significantly.
The company's losses roughly doubled year-over-year despite meaningfully lower R&D spending, indicating potential operational inefficiencies or one-time charges that warrant investigation. With cash reserves declining from $471M to $308M and minimal revenue generation, PRTA faces mounting pressure to achieve meaningful clinical milestones or secure additional funding to sustain operations.
PRTA experienced a challenging financial year with losses substantially increasing while R&D expenses declined by nearly 40%, suggesting the higher losses stem from factors beyond core research spending. The company's balance sheet weakened considerably with total assets falling from $547M to $327M, driven primarily by the significant cash burn that reduced liquidity by over $160M. Despite lower liabilities providing some relief, the combination of dramatically higher losses and substantial cash depletion signals heightened financial stress for this biotech company.
Net income declined 99.6% — review whether driven by operations, interest costs, or non-recurring items.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Total assets contracted 40.3% — asset sales, write-downs, or balance sheet optimization underway.
R&D spending cut 39.4% — could signal cost discipline or concerning reduction in innovation investment.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Current assets declined 35.1% — monitor working capital adequacy and short-term liquidity.
Cash declined 34.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Liabilities reduced 23% — deleveraging improves balance sheet strength and financial flexibility.
Current liabilities reduced — improved short-term financial position and working capital health.
Revenue softened 14.8% — monitor whether this is cyclical or structural.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →